Development

Kim Gaspar, PhD, is manager of quality assurance at Helix BioPharma.

Jinghui Shen, B. Eng., is an analytical chemist at Helix BioPharma.

John Docherty, M. Sc., is president and chief operating officer at Helix BioPharma.

Ravinderjit Batta, M. Pharm., is group leader of formulation development at Helix BioPharma.

Geriene LaBine, M. Sc., is head of quality control at Helix BioPharma.

Praveen Kumar, M. Pharm. and PhD, is vice-president of topical drug product development at Helix BioPharma, 301â111 Research Drive, Innovation Place, Saskatoon, Saskatchewan, Canada S7N 3R2, tel. 306.934.7471 ext 230, fax 306.934.7453.

Marianna Foldvari, D. Pharm. Sci. and PhD, is Canada research chair in bionanotechnology and nanomedicine and associate director of research and graduate studies at the School of Pharmacy, University of Waterloo, Ontario, Canada.

Articles

The authors describe a proprietary process for producing a stable, topical interferon alpha-2b formulation that can deliver large drug molecules into the skin or mucosa.

Stabilization of Interferon alpha-2b in a Topical Cream

David W. Osborne, PhD, is Chief Scientific Officer and Founder, Independent Derm Solutions, LLC, 4215 Creekside Court, Fort Collins, CO 80525.

This article summarizes the classification systems for topical liquid and semisolid dosage forms used for dermatological application and notes some differences between FDA and USP classification.

Review of Changes in Topical Drug Product Classification

Anil K. Singla, PhD, is a professor and chairman at the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India, tel/fax +91 172 541142.

Extensive research has been conducted to improve the solubility and permeability of acetazolamide in hopes that a topical formulation for the treatment of glaucoma can be developed.

Formulation and Drug Delivery, Topical Drugs